Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 535-541

  Yang, Xin Yu ^a   Zeng, Hui ^b   Chen, Fang Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Cytokine induced killer cells; Leukemia

Indexed keywords

ALPHA INTERFERON; CHIMERIC ANTIGEN RECEPTOR; CINNAMALDEHYDE; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 24; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; RESVERATROL; THYMOCYTE ANTIBODY; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHEMOTHERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE INDUCED KILLER CELL; GENE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84918796688     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2780     Document Type: Article

References (58)

1. Burnett AK, Kell WJ, Goldstone AH, et al: The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 Trial. ASH Annual Meeting Abstracts 108: 13, 2006.
2. Bassan R, Spinelli O, Oldani E, et al: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113: 4153-4162, 2009.
3. Oran B and de Lima M: Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 18: 388-394, 2011.
4. Brentjens RJ, Rivière I, Park J H, et al: Safety and persistence of adoptively transferred autologous CD19- targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828, 2011.
5. Ruggeri L, Mancusi A, Burchielli E, et al: Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 8: 554-558, 2006.
6. Colvin GA, Berz D, Ramanathan M, et al: Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 15: 421-431, 2009.
7. Warlick ED, DeFor T, Blazar BR, et al: Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 18: 480-486, 2012.
8. Barrett AJ and Le Blanc K: Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 161: 223-232, 2010.
9. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
10. Vivier E, Ugolini S, Blaise D, et al: Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12: 239-252, 2012.
11. Gütgemann S, Frank S, Strehl J and Schmidt-Wolf IG: Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci 5: Doc 07, 2007.
12. Sangiolo D, Martinuzzi E, Todorovic M, et al: Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 20: 841-848, 2008.
13. Kim HM, Kang JS, Lim J, et al: Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res 32: 781-787, 2009.
14. Linn YC, Lau SK, Liu BH, et al: Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 126: 423-435, 2009.
15. Franceschetti M, Pievani A, Borleri G, et al: Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 37: 616-628, 2009.
16. Verneris MR: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072, 2004.
17. Linn YC, Wang SM and Hui KM: Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol 33: 671-681, 2005.
18. Pievani A, Borleri G, Pende D, et al: Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118: 3301-3310, 2011.
19. Yu J, Zhang W, Jiang H, et al: CD4+ T cells in CIKs (CD4+ CIKs) reversed resistance to Fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm 23: 342-354, 2008.
20. Hoyle C, Bangs CD, Chang P, et al: Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318-3327, 1998.
21. Linn YC, Lau LC and Hui KM: Generation of cytokine-induced killer cells from leukemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116: 78-86, 2002.
22. Kornacker M, Moldenhauer G, Herbst M, et al: Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 119: 1377-1382, 2006.
23. Scheffold C, Brandt K, Johnston V, et al: Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15: 33-39, 1995.
24. Nishimura R, Baker J, Beilhack A, et al: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112: 2563-2574, 2008.
25. Sangiolo D, Mesiano G, Carnevale-Schianca F, et al: Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 9: 831-840, 2009.
26. Mase S, Fujiki T, Kuroda R, Araki R, et al: Allogeneic cytokine-induced killer cells eliminate host dendritic cells due to the enhanced killing activity by IFN-gamma, leading to less graft-versus-host disease. Blood 122: 4495, 2013.
27. Yun YS, Hargrove ME and Ting CC: In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49: 4770-4774, 1989.
28. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, et al: Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 12: 569-576 2006.
29. Schmidt-Wolf GD, Negrin RS and Schmidt-Wolf IG: Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74: 51-56, 1997.
30. Raulet DH, Gasser S, Gowen BG, et al: Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31: 413-441, 2013.
31. Vesely MD and Schreiber RD: Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann NY Acad Sci 1284: 1-5, 2013.
32. Huang B, Sikorski R, Sampath P and Thorne SH: Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 34: 289-296, 2011.
33. Wang QJ, Wang H, Pan K, et al: Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 29: 641-648, 2010.
34. Ge W, Li CH, Zhang W, et al: Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo. Zhonghua Xue Ye Xue Za Zhi 25: 277-280, 2004 (In Chinese).
35. Rettinger E, Kuçi S, Naumann I, et al: The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14: 91-103, 2012.
36. Zhao N, Zhao MF, Rajbhandary S, et al: Effects of humanized interleukin 21 on anti-leukemic activity of cytokine induced killer cells and the mechanism. Zhonghua Xue Ye Xue Za Zhi 33: 823-828, 2012 (In Chinese).
37. Durrieu L, Gregoire-Gauthier J, Dieng MM, et al: Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 14: 1245-1257, 2012.
38. Xia W, Yu X, Wang P, et al: The cytotoxicity of IL-24 gene-modified CIK cells to HL-60 cells. Chin J Immunol 25: 1080-1084, 2009.
39. Marin V, Kakuda H, Dander E, et al: Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol 35: 1388-1397, 2007.
40. Marin V, Pizzitola I, Agostoni V, et al: Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95: 2144-2152, 2010.
41. Tettamanti S, Marin V, Pizzitola I, et al: Targeting of acute myeloid leukaemia by cytokine. Induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Bri J Haematol 161: 389-401, 2013.
42. Hu L, Cao D, Li Y, et al: Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer Biol Ther 13: 516-526, 2012.
43. Zhang JH, Liu LQ, He YL, et al: Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells. Acta Pharmacol Sin 31: 861-866, 2010.
44. Kaneko T, Fusauch Y, Kakui Y, et al: Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk Lymphoma 14: 219-229, 1994.
45. Bonanno G, Iudicone P, Mariotti A, et al: Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med 8: 129, 2010.
46. Zheng Z, Yuna Z, Huimin Z, Liu Q, et al: Clinical study of DC-CIK (dendritic cells and cytokine-induced killer cells) eliminate minimal residual leukemia. Blood 122: 1450, 2013.
47. Thanendrarajan S, Nowak M, Abken H and Schmidt-Wolf IG: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? Leuk Res 35: 1136-1142, 2011.
48. Yang Z, Zhang Q, Xu K, et al: Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One 7: e44802, 2012.
49. Niam M, Linn YC, Fook Chong S, et al: Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 39: 897-903, 2011.
50. Introna M, Borleri G, Conti E, et al: Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92: 952-959, 2007.
51. Introna M, Pievani A, Borleri G, et al: Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 16: 1603-1607, 2010.
52. Linn YC, Niam M, Chu S, et al: The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 47: 957-966, 2012.
53. Linn YC, Yong HX, Niam M, et al: A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy 14: 851-859, 2012.
54. Zhong R, Teng J, Han B and Zhong H: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502, 2011.
55. Jiang H, Liu KY, Tong CR, et al: The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi 44: 198-201, 2005 (In Chinese).
56. Benjamin J, Laport GG, Tate K, Galvez L, et al: Early infusion of donor-derived CIK cells as consolidative immunotherapy following non-myeloablative allogeneic transplantation: safety and feasibility. Blood 122: 899, 2013.
57. Zhou X, Zhu J, Sun H, et al: Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting. Leukemia Lymphoma 54: 209-211, 2013.
58. Hontscha C, Borck Y, Zhou H, et al: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-331, 2011.